Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 807 results for "Treatment For Ovarian Cancer"

Setback for Abiraterone Acetate in Recurrent Ovarian Cancer
Targeted Oncology

Setback for Abiraterone Acetate in Recurrent Ovarian Cancer

Susanna Banerjee, PhD Although one patient with recurrent ovarian cancer achieved complete response,the first trial of abiraterone conducted in ovarian cancer was halted early due to low response, according to results from the CORAL phase 2 trial ... Targeted Oncology, 2 weeks ago

47 images for Treatment For Ovarian Cancer

News, 1 week ago
Cancer Therapy Advisor, 3 weeks ago
Pharmafile, 2 days ago
MedIndia, 1 month ago
BBC, 1 week ago
Cancer Therapy Advisor, 2 months ago, 2 weeks ago
PharmaVOICE, 3 months ago
BioSpace, 2 weeks ago
Yahoo! Singapore, 2 weeks ago

Bride With Cancer Asks For Donations To Fun Treatment Instead Of Traditional Wedding Gifts

She wants help to fund treatment which costs £114,000 per year. A woman with cancer, who is getting married this weekend, has asked people to raise money for her to have life-saving treatment instead of offering traditional wedding gifts. Emma ...
 Huffington Post UK2 weeks ago Bride-To-Be With Ovarian Cancer Asks For Donations For Treatment Costs Instead Of Traditional Wedding Gifts  Huffington Post UK2 weeks ago
Cancer Therapy Advisor

Niraparib Maintenance Prolongs PFS in Recurrent Ovarian Cancer

Share this content: Maintenance therapy with niraparib significantly prolongs progression-free survival for all study populations of patients with recurrent ovarian cancer. Maintenance therapy with niraparib significantly prolongs ...
 Cancer Therapy Advisor2 weeks ago ESMO 2016 Complete Coverage  Cancer Therapy Advisor2 weeks ago Financial difficulties may impact treatment outcomes for cancer patients  News-Medical.Net2 weeks ago Niraparib Highly Effective as Maintenance Therapy for Recurrent Ovarian Cancer  Equilibrio Informativo2 weeks ago

'Qigong master' swindles, accelerates death of cancer patient

Ms. Zhang, a 61-year-old woman with inoperable ovarian cancer, recently passed away after going through Qigong treatment, imposed by a quack specialist. Discomfort first manifested in Zhang's right shoulder. As the pain grew worse, she resorted to ... weeks ago

Tesaro Jumped on PARP Ovarian Cancer Win Vs. AstraZeneca PLC, AbbVie

By Alex Keown , Breaking News Staff WALTHAM, Mass. Since June shares of Tesaro Inc. ( TSRO ) have soared, nearly tripling in price since early July when the company announced its ovarian cancer treatment, Niraparib , an oral, ...
 BioSpace2 weeks ago Bay State Biotech Report: Tesaro and Ariad  Bloomberg2 weeks ago Tesaro: Priced for a Takeover?  Pettinga Financial Advisors2 weeks ago Tesaro jumps on PARP ovarian cancer data, as drug hailed a breakthrough  FierceBiotech2 weeks ago

Canada denies access to ovarian cancer drug Lynparza

MISSISSAUGA, ON Following its deliberations, the pan-Canadian Oncology Drug Review (pCODR) recently announced its decision not to recommend for provincial reimbursement, Lynparza (olaparib), a maintenance treatment for women with platinum-sensitive ...
 Can India News3 weeks ago Canada Denies Public Access To Potentially Life-Prolonging Ovarian Cancer Treatment LYNPARZA® (olaparib)  Yahoo! Finance3 weeks ago AstraZeneca Canada Release: Canada Denies Public Access To Potentially Life-Prolonging Ovarian Cancer Treatment LYNPARZA (Olaparib)  BioSpace3 weeks ago

‘Contraceptives reduce ovarian cancer deaths’

Widespread use of oral contraceptives is driving the fall in the number of deaths from ovarian cancer worldwide, according to a new study published on Tuesday. Deaths from ovarian cancer fell world-wide between 2002 and 2012 and are predicted to continue to ...
 Asian Age1 month ago Contraceptive pills driving fall in ovarian cancer deaths  Business Standard1 month ago

Adaptimmune revives ovarian cancer trial

T-cell therapy specialist Adaptimmune Therapeutics has said an ovarian cancer trial has been revived after it changed a chemotherapy regimen used to pre-condition patients. The company, which is partnering with GlaxoSmithKline, had found that the ...
 pharmaphorum2 weeks ago Adaptimmune Makes Move to Save Ovarian Cancer Study By Readjusting Its Trial Protocol  BioSpace2 weeks ago After setback, Adaptimmune revamps T cell study  BioPharma Dive2 weeks ago Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer  BioSpace2 weeks ago

Karolinska Development AB Portfolio Company Aprea Enrolls First Patients In Phase II Trial Of APR-246 In Ovarian Cancer

. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Aprea Therapeutics AB announced today that it enrolled the first patients in the Phase II part of the ongoing PiSARRO clinical study of APR-246 for the ...
 BioSpace2 weeks ago Karolinska Development portfolio company Aprea Therapeutics enrolls first patients in Phase II trial of APR-246 in ovarian cancer  Forex TV2 weeks ago Novocure Enrolls First Patient in Phase 3 Pivotal Brain Metastases Trial  BizWire Express2 weeks ago Aprea Therapeutics enrols first patients for Phase II study of APR-246 for ovarian cancer treatment  Drug Development Technology2 weeks ago
International Business Times

Aprea Therapeutics Announces Efficacy and Safety Data in High-Grade Serous Ovarian Cancer Patients Treated with APR-246 in Presentation at 2016 European Society for Medical Oncology (ESMO) Annual Meet

BOSTON and STOCKHOLM, Oct. 10, 2016 /PRNewswire/ -- , a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today presented clinical data from the Phase Ib part ...
 International Business Times2 weeks ago Aprea Therapeutics Announces First Patients Enrolled in Phase II Clinical Study of APR-246 for the Treatment of High-Grade Serous Ovarian Cancer  International Business Times2 weeks ago Aprea Therapeutics begins first patients enrollment in phase II study of APR-246 to treat high-grade serous ovarian cancer  PharmaBiz2 weeks ago Aprea Announces First Patients Enrolled In Phase II Clinical Study Of APR-246 For The Treatment Of High-Grade Serous Ovarian Cancer  BioSpace2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Treatment For Ovarian Cancer
Get updated on latest news & your favorite topics right in your inbox!
Happening by Location Click on any location on map to view latest news by location
More     Less